Aizhen Wu

Title: Aizhen Wu: Innovator in Insulinotropic GLP-1 Polypeptide Production

Introduction

Aizhen Wu is a prominent inventor based in Shanghai, China. She has made significant contributions to the field of biotechnology, particularly in the production of insulinotropic GLP-1 polypeptides. Her innovative methods have the potential to enhance the efficiency and cost-effectiveness of recombinant polypeptide production.

Latest Patents

Aizhen Wu holds a patent for the "Method of producing insulinotropic GLP-1 (7-36) polypeptide and/or GLP-1 analogs." This invention discloses a method for producing polypeptides by ligating genes in a tandem manner. The method allows for the expression of 1 to 32 copies of GLP-1 (7-36) and/or GLP-1 analog genes in tandem. The desired polypeptide can be obtained after cleavage of a fusion protein and further processes of separation and purification. This innovation makes it possible to produce recombinant polypeptides, including recombinant GLP-1 (7-36) and/or GLP-1 analogs on a large scale, significantly reducing production costs.

Career Highlights

Aizhen Wu is affiliated with Shanghai Hua Yi Bio-tech Lab, where she continues to advance her research and development efforts. Her work has positioned her as a key figure in the biotechnology sector, particularly in the area of peptide synthesis and production.

Collaborations

Aizhen collaborates with notable colleagues, including Yukun Sun and Dengxi Wu. Their combined expertise contributes to the innovative research and development initiatives at Shanghai Hua Yi Bio-tech Lab.

Conclusion

Aizhen Wu's contributions to the field of biotechnology, particularly through her patented methods for producing insulinotropic GLP-1 polypeptides, highlight her role as an influential inventor. Her work not only advances scientific knowledge but also has practical implications for the production of important therapeutic agents.